If you have been living with loud snoring, gasping awake at night, or exhausting days despite what feels like a full night of sleep, you may already suspect you have obstructive sleep apnea. What you may not know is that Zepbound (tirzepatide), already familiar to many Long Island patients as a weight loss injection, is now FDA-approved to treat obstructive sleep apnea directly. At Long Island Weight Loss Institute (LIWLI), we are seeing this connection firsthand: a growing number of our Zepbound patients were approved for treatment specifically because of their sleep apnea diagnosis, not weight loss alone.
What Is Obstructive Sleep Apnea, and How Is It Connected to Weight?
Obstructive sleep apnea happens when the muscles in the back of your throat relax too much while you sleep, letting your airway collapse and blocking your breathing. Each pause can last several seconds and may happen dozens of times an hour, breaking up your sleep even if you never fully wake up and remember it. Carrying extra weight is one of the biggest risk factors, because extra tissue around the neck and throat narrows the airway and makes it easier to collapse. According to the National Heart, Lung, and Blood Institute, sleep apnea affects more than 80 percent of people who have both obesity and type 2 diabetes, which shows just how closely tied it is to weight and metabolism.
That connection is exactly why an effective weight loss treatment can also be an effective sleep apnea treatment. Losing that excess tissue around your airway does not just change how you look. It changes how well you breathe at night.
Is Zepbound FDA-Approved for Sleep Apnea?
Yes. In December 2024, the FDA approved Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity, according to Eli Lilly’s official announcement. This made Zepbound (tirzepatide) the first medication ever approved specifically for obstructive sleep apnea, not just for weight loss. The approval covers adults with obesity who have been diagnosed with moderate-to-severe OSA, whether or not they currently use a CPAP machine.
This matters for how your prescription is written and how your insurance may look at coverage, since it gives your doctor a clear, FDA-recognized reason to prescribe Zepbound for your sleep, not only for weight loss.
What Did the Clinical Trial Show?
The approval was based on a year-long study of adults with moderate-to-severe sleep apnea and obesity, some using a CPAP machine and some not. According to Eli Lilly’s approval announcement, patients taking Zepbound had at least 25 fewer breathing interruptions every hour they slept, while losing an average of up to 20 percent of their body weight. After a year, as many as half of the patients on Zepbound no longer had symptoms of sleep apnea at all.
Patients also saw improvements in blood pressure and other health markers along the way, on top of the changes in their sleep.
How Does Weight Loss From Zepbound Improve Sleep Apnea?
Zepbound works by curbing appetite and helping your body burn through fat stores more effectively. As you lose weight, the tissue around your neck and throat shrinks along with the rest of your body, and that is often what was narrowing your airway and causing it to collapse during sleep in the first place.
Less tissue crowding the airway means fewer of those breathing pauses each night. Many patients also tell us that once their sleep improves, everything else gets a little easier: more energy for exercise, steadier moods, and an easier time sticking with healthier eating habits, which in turn supports the weight loss.
Who Might Be a Candidate for Zepbound Treatment on Long Island?
This approval is for adults with obesity who have been diagnosed with moderate-to-severe obstructive sleep apnea, usually through a sleep study. At LIWLI, our providers look at your sleep apnea diagnosis, your weight history, and your overall health to see whether Zepbound or another GLP-1 treatment is a good fit, and we work with sleep specialists if you need a formal diagnosis or an updated sleep study before starting.
You do not need to have already tried CPAP and given up on it to be a candidate, though plenty of our patients come to us after finding CPAP uncomfortable or hard to stick with. Some patients keep using CPAP alongside Zepbound, while others need it less over time as their weight and sleep apnea improve. That is a decision you will make together with your doctor, based on your own sleep study results.
What Should You Expect When Starting Treatment?
Zepbound starts at a low weekly dose and increases gradually over several months, whether it is prescribed for weight loss or for sleep apnea. Starting low and increasing slowly helps keep early side effects like nausea and an upset stomach more manageable.
Your sleep apnea tends to improve alongside your weight loss rather than overnight, so most patients notice snoring, daytime tiredness, and sleep quality getting better gradually over the first few months, not right away. Regular check-ins with your provider, including a repeat sleep study when it makes sense, will help confirm how much your sleep apnea has actually improved and whether your CPAP use should change.
The Bottom Line for Long Island Patients
Zepbound is now the first and only medication approved specifically for obstructive sleep apnea in adults with obesity, and the results behind that approval are substantial. If snoring, exhausting days, or a difficult relationship with CPAP have been part of your life along with a weight struggle, it is worth a direct conversation with your doctor. Long Island Weight Loss Institute offers physician-supervised evaluations for Zepbound and other GLP-1 treatments at our East Meadow, Amityville, Smithtown, and Port Jefferson Station locations, as well as through telehealth visits across Long Island. Request a consultation today to find out whether Zepbound could be the right treatment for your sleep apnea and your weight loss goals.